4//SEC Filing
VanDevender Aaron 4
Accession 0001209191-23-059942
CIK 0001801777other
Filed
Dec 27, 7:00 PM ET
Accepted
Dec 28, 5:39 PM ET
Size
12.3 KB
Accession
0001209191-23-059942
Insider Transaction Report
Form 4
VanDevender Aaron
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−15,395→ 0 totalExercise: $47.01Exp: 2031-05-18→ Common Stock (15,395 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−20,000→ 0 totalExercise: $0.34Exp: 2033-06-14→ Common Stock (20,000 underlying) - Disposition to Issuer
Common Stock
2023-12-27−212,659→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−20,000→ 0 totalExercise: $3.13Exp: 2032-05-24→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger dated as of September 21,2023 (the "Merger Agreement") by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of common stock was tendered in exchange for 0.1331 of a share of Cyclo common stock (the "Transaction Consideration"). Upon consummation of the tender offer, the Reporting Person received Transaction Consideration of 28,305 shares of Cyclo common stock.
- [F2]Pursuant to the the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
- [F3]Pursuant to the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.
Documents
Issuer
Applied Molecular Transport Inc.
CIK 0001801777
Entity typeother
Related Parties
1- filerCIK 0001813427
Filing Metadata
- Form type
- 4
- Filed
- Dec 27, 7:00 PM ET
- Accepted
- Dec 28, 5:39 PM ET
- Size
- 12.3 KB